论文部分内容阅读
目的:评估自体DC与CIK细胞治疗难治复发急性髓细胞白血病的近期疗效与安全性。方法:给予20例难治复发急性髓细胞白血病患者树突状细胞(DC)与细胞因子诱导的杀伤细胞(CIK)治疗,20例难治复发的应用同样化疗方案的急性髓细胞白血病患者做为对照组;治疗后4周观察两组患者临床疗效和生存质量(KPS)评分,DC与CIK细胞治疗前和治疗后1周检测T细胞亚群(CD3+、CD3+CD4+、CD3+CD8+、CD3+CD56+)和细胞因子(IL-12、IL-2、IL-7、IFN-γ及TNF-α)水平的变化。结果:①DC与CIK细胞治疗组有效率和KPS评分明显高于对照组(P<0.05),所有患者的不良反应轻微,均可耐受。②DC与CIK细胞治疗后1周,患者T细胞亚群百分比和细胞因子含量较治疗前均明显升高,其中CD3+、CD3+CD56+及IL-12、IL-7明显升高(P<0.05)。结论:DC与CIK细胞免疫治疗难治复发急性髓细胞白血病安全有效。
Objective: To evaluate the short-term efficacy and safety of autologous DC and CIK cells in the treatment of refractory recurrent acute myeloid leukemia. Methods: Dendritic cells (DCs) and cytokine-induced killer cells (CIKs) were treated in 20 patients with refractory relapsed acute myeloid leukemia. Twenty patients with refractory relapse treated with the same chemotherapeutic regimen of acute myeloid leukemia Control group. The clinical curative effect and quality of life (KPS) scores of two groups were observed 4 weeks after treatment. T cell subsets (CD3 +, CD3 + CD4 +, CD3 + CD8 +, CD3 + CD56 +) and cytokines (IL-12, IL-2, IL-7, IFN-γ and TNF-α). Results: ① The effective rate and KPS score of DC and CIK cell treatment group were significantly higher than those of control group (P <0.05). All patients had slight adverse reaction and could tolerate. ② After 1 week of treatment of DC and CIK cells, the percentage of T lymphocyte subsets and cytokines were significantly higher than those before treatment, and the levels of CD3 +, CD3 + CD56 +, IL-12 and IL-7 were significantly increased (P <0.05). Conclusions: DC and CIK cell immunotherapy is safe and effective in refractory recurrent acute myeloid leukemia.